Publication:
Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up

Simple item page
dc.contributor.authorDİNÇER YAZAN, CEYDA
dc.contributor.authorBUĞDAYCI, ONUR
dc.contributor.authorILGIN, CAN
dc.contributor.authorYAVUZ, DİLEK
dc.contributor.authorsDİNÇER YAZAN C., BUĞDAYCI O., ILGIN C., YAVUZ D.
dc.date.accessioned2022-09-26T11:39:23Z
dc.date.available2022-09-26T11:39:23Z
dc.date.issued2022-12-01
dc.description.abstractSummary Denosumab leads to improvements in BMD levels and is a well-tolerated agent according to results of randomized controlled studies but results in real-life setting are important to evaluate drug adherence and real-life efciency. In this study, we present the results of 305 patients that were treated with denosumab in our clinic. Introduction The long-term efcacy of anti-osteoclastic drugs in treatment of osteoporosis is well known. Denosumab, a novel human monoclonal antibody, is an anti-osteoclastic agent that has been shown to lead to reductions in vertebral, nonvertebral, and hip fracture risk in randomized and observational studies. Real-life data of this agent is increasing. In this study, we presented our real-life data about the 2-year follow-up of patients under denosumab treatment. Methods Osteoporotic patients who were treated with at least one denosumab injection between 2014 and 2020 years were included. Clinical and demographic data, bone turnover markers, and radiological reports (bone mineral densitometry (BMD), vertebral x-ray) were obtained from patient fles retrospectively. Results A total of 305 patients (f/m: 275/30, 68.1±11.05 years) were included. The median injection number was 4 (1–10). Two hundred seventy-three patients (89.8%) were persistent on treatment at the 12th month; 175 patients (57.3%) were persistent at 24th month. Sixty-eight patients (22%) were not using denosumab anymore, 55 of the patients were not continuing by doctor desicion and 13 were not continuing due to patient-related causes. Median BMD levels signifcantly increased from 0.809 (0.2–1.601, IQR: 0.136) to 0.861 (0.517–1.607, IQR: 0.14) in L1–L4 and from 0.702 (0.349–0.997, IQR: 0.125) to 0.745 (0.508–1.008, IQR: 0.137) in femur area at the 24th month of treatment. An improvement of 8.04% in L1–L4 BMD and 4.5% in femur neck BMD levels at the 24th month of treatment was observed. There was a signifcant decrease in bone turnover markers at the 24th month of treatment. Conclusion In our group of patients under denosumab treatment, 53% of persistence was found at 24 months and associated with improvement in BMD levels without any signifcant side efects except one case with urticarial reaction. Denosumab leads to improvements in BMD levels and is a well-tolerated agent in a real-life setting comparable to results of randomized controlled studies in patients with diferent comorbidities.
dc.identifier.citationDİNÇER YAZAN C., BUĞDAYCI O., ILGIN C., YAVUZ D., "Effect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up", ARCHIVES OF OSTEOPOROSIS, cilt.17, sa.1, 2022
dc.identifier.doi10.1007/s11657-022-01145-2
dc.identifier.issn1862-3522
dc.identifier.issue1
dc.identifier.urihttps://hdl.handle.net/11424/281775
dc.identifier.volume17
dc.language.isoeng
dc.relation.ispartofARCHIVES OF OSTEOPOROSIS
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTıp
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectEndokrinoloji ve Metabolizma Hastalıkları
dc.subjectCerrahi Tıp Bilimleri
dc.subjectOrtopedi ve Travmatoloji
dc.subjectSağlık Bilimleri
dc.subjectMedicine
dc.subjectInternal Medicine Sciences
dc.subjectInternal Diseases
dc.subjectEndocrinology and Metabolic Diseases
dc.subjectSurgery Medicine Sciences
dc.subjectOrthopedics and Traumatology
dc.subjectHealth Sciences
dc.subjectENDOKRİNOLOJİ VE METABOLİZMA
dc.subjectKlinik Tıp
dc.subjectKlinik Tıp (MED)
dc.subjectORTOPEDİ
dc.subjectENDOCRINOLOGY & METABOLISM
dc.subjectCLINICAL MEDICINE
dc.subjectClinical Medicine (MED)
dc.subjectORTHOPEDICS
dc.subjectAyak Bakımı
dc.subjectEndokrin ve Otonom Sistemler
dc.subjectOrtopedi ve Spor Hekimliği
dc.subjectEndokrinoloji, Diyabet ve Metabolizma
dc.subjectEndokrinoloji
dc.subjectYaşam Bilimleri
dc.subjectPodiatry
dc.subjectEndocrine and Autonomic Systems
dc.subjectOrthopedics and Sports Medicine
dc.subjectEndocrinology, Diabetes and Metabolism
dc.subjectEndocrinology
dc.subjectLife Sciences
dc.subjectDenosumab
dc.subjectBone mineral density
dc.subjectReal-life experience
dc.titleEffect of denosumab treatment on bone mineral density and bone turnover markers in osteoporotic patients: real-life experience 2-year follow-up
dc.typearticle
dspace.entity.typePublication
local.avesis.idb5c114e4-7c1e-4501-beb9-a593e72127d2
local.indexed.atPUBMED
relation.isAuthorOfPublicationfba137dc-334b-4dba-aeae-fcfae74846d9
relation.isAuthorOfPublication09a6d1f6-4818-4911-b69c-bd4ece9c9d3a
relation.isAuthorOfPublication380f62e4-4745-4e22-b9c9-67cb0373648d
relation.isAuthorOfPublication26174ec5-7dca-4038-a7fe-9a43f236fd15
relation.isAuthorOfPublication.latestForDiscoveryfba137dc-334b-4dba-aeae-fcfae74846d9

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
aa.pdf
Size:
588.51 KB
Format:
Adobe Portable Document Format
Download

Collections

Research Outputs